companies

uMed

Founded 2017
Employees 70+
Primary contact
8 Warner Yard
EC1R 5EY London
United Kingdom
Links
https://umed.io/
Sections
uMed is a healthcare technology company dedicated to accelerating clinical trials by making participation in research more accessible for healthcare professionals and their patients. The uMed platform takes on the workload of recruiting patients for clinical studies by automating the process of identification, screening, and engagement, all on behalf of the patient's recognized provider. The technology seamlessly links clinical data from consented patients to ePROs, device data, and biosamples to rapidly create study-specific datasets and registries. This enables healthcare professionals to participate in more revenue-generating research with minimal additional workload, and provides patients with better access to life-changing studies. uMed is embedded across a global network of providers that represent over 10 million lives across the UK, US, Canada and Australia. In addition to its headquarters in London, the company has an office in New York.
Founded 2017
Employees 70+
Primary contact
8 Warner Yard
EC1R 5EY London
United Kingdom
Links
https://umed.io/
Sections

Funding 💰

Total $18.3M
Last round 🔗 £9.8M
Other
July 5, 2023.
Select investors Playfair Capital, AlbionVC, PharmStars, 11.2 Capital, Delin Ventures

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Solving the problem: Patient access to industry clinical trials has dropped by 44% between 2017/18 and 2021/22, and the number of trials initiated in the UK (including cancer trials) plummeted by 41% in a similar time frame. This is raising alarm about the future of clinical research in the UK and the resulting impact on patient care. uMed directly tackles this issue by enabling healthcare providers in the UK, US and Canada to more easily participate in clinical research and care improvement activity without additional cost or burden to staff.
  • It works: Since its 2020 seed round, uMed's technology has enabled a number of successful nationwide studies to take place across the UK, including a prospective precision medicine clinical trial for patients with high hypertension and a nationwide study into identifying the risk of Parkinson's Disease.
  • The North America expansion: On the heels of its funding announcement in July 2023, the company announced further expansion in North America, spearheaded by a partnership deal with digital healthcare company Innovaccer. As a result, uMed got access to over seven million patients across the country. This follows uMed's inaugural Canadian partnership with clinician-led healthtech MCI Onehealth and is part of the effort to gain access to over 10 million patients by the end of 2023. 🔗

Video ▶️

Awards & Recognitions 🏆

  • 2020 BusinessCloud's 100 HealthTech Pioneers: Among the Top 20 companies 🔗

Quotes 💬

“
At AlbionVC we are thrilled to continue partnering with Matt Wilson and his team to enable longitudinal research which has historically taken decades and cost millions of pounds. uMed's technology is uniquely positioned to truly revolutionise how clinical research is conducted globally. The latest round of funding will continue to support the company's US expansion and will further accelerate the next phase of growth on a path to global category leadership.
— Molly Gilmartin, Investor at AlbionVC 🔗
“
Delin Ventures is delighted to continue supporting uMed's team in executing our shared vision, deploying digital health technology to revolutionise the future of trials and medical insight generation on a global scale – focusing now on the US. The traditional clinical research model is slow and expensive. uMed provides a unique platform to engage patients at scale in a highly targeted and cost-effective manner.
— Rosie Barnett, Principal at Delin Ventures 🔗
Last update: July 18, 2023